276 related articles for article (PubMed ID: 27037933)
1. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.
Byrd KM; Subramanian C; Sanchez J; Motiwala HF; Liu W; Cohen MS; Holzbeierlein J; Blagg BS
Chemistry; 2016 May; 22(20):6921-31. PubMed ID: 27037933
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.
Kusuma BR; Khandelwal A; Gu W; Brown D; Liu W; Vielhauer G; Holzbeierlein J; Blagg BS
Bioorg Med Chem; 2014 Feb; 22(4):1441-9. PubMed ID: 24461493
[TBL] [Abstract][Full Text] [Related]
3. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.
Zhao H; Donnelly AC; Kusuma BR; Brandt GE; Brown D; Rajewski RA; Vielhauer G; Holzbeierlein J; Cohen MS; Blagg BS
J Med Chem; 2011 Jun; 54(11):3839-53. PubMed ID: 21553822
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.
Burlison JA; Blagg BS
Org Lett; 2006 Oct; 8(21):4855-8. PubMed ID: 17020320
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
[TBL] [Abstract][Full Text] [Related]
6. Novobiocin Analogues That Inhibit the MAPK Pathway.
Hall JA; Seedarala S; Zhao H; Garg G; Ghosh S; Blagg BS
J Med Chem; 2016 Feb; 59(3):925-33. PubMed ID: 26745854
[TBL] [Abstract][Full Text] [Related]
7. Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.
Peterson LB; Blagg BS
Bioorg Med Chem Lett; 2010 Jul; 20(13):3957-60. PubMed ID: 20570149
[TBL] [Abstract][Full Text] [Related]
8. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.
Kusuma BR; Duerfeldt AS; Blagg BS
Bioorg Med Chem Lett; 2011 Dec; 21(23):7170-4. PubMed ID: 22014546
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.
Audisio D; Methy-Gonnot D; Radanyi C; Renoir JM; Denis S; Sauvage F; Vergnaud-Gauduchon J; Brion JD; Messaoudi S; Alami M
Eur J Med Chem; 2014 Aug; 83():498-507. PubMed ID: 24992077
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitors identified from a library of novobiocin analogues.
Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS
J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253
[TBL] [Abstract][Full Text] [Related]
12. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
Le Bras G; Radanyi C; Peyrat JF; Brion JD; Alami M; Marsaud V; Stella B; Renoir JM
J Med Chem; 2007 Nov; 50(24):6189-200. PubMed ID: 17979263
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).
Radanyi C; Le Bras G; Messaoudi S; Bouclier C; Peyrat JF; Brion JD; Marsaud V; Renoir JM; Alami M
Bioorg Med Chem Lett; 2008 Apr; 18(7):2495-8. PubMed ID: 18304811
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors.
Garg G; Zhao H; Blagg BS
Bioorg Med Chem; 2017 Jan; 25(2):451-457. PubMed ID: 27914946
[TBL] [Abstract][Full Text] [Related]
15. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
16. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer.
Forsberg LK; Liu W; Holzbeierlein J; Blagg BSJ
Bioorg Med Chem Lett; 2017 Sep; 27(18):4514-4519. PubMed ID: 28844386
[TBL] [Abstract][Full Text] [Related]
17. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization.
Allan RK; Mok D; Ward BK; Ratajczak T
J Biol Chem; 2006 Mar; 281(11):7161-71. PubMed ID: 16421106
[TBL] [Abstract][Full Text] [Related]
18. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.
Garg G; Forsberg LK; Zhao H; Blagg BSJ
Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.
Byrd KM; Kent CN; Blagg BSJ
ChemMedChem; 2017 Dec; 12(24):2022-2029. PubMed ID: 29058824
[TBL] [Abstract][Full Text] [Related]
20. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.
Marcu MG; Schulte TW; Neckers L
J Natl Cancer Inst; 2000 Feb; 92(3):242-8. PubMed ID: 10655441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
